Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting 5-10 % of women of reproductive age. It generally manifests with oligo/anovulatory cycles, hirsutism and polycystic ovaries, ...together with a considerable prevalence of insulin resistance. Although the aetiology of the syndrome is not completely understood yet, PCOS is considered a multifactorial disorder with various genetic, endocrine and environmental abnormalities. Moreover, PCOS patients have a higher risk of metabolic and cardiovascular diseases and their related morbidity, if compared to the general population.
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting 5-10% of women of reproductive age. It generally shows with oligo/amenorrhea, anovulatory cycles, clinical o biochemical ...hirsutism, polycystic ovaries and, in a significant percentage of cases, insulin resistance. PCOS is defined as a multifactorial pathology, determined by the association of many factors: genetic, endocrine and environmental.
The first and most effective treatment of PCOS is to change life-style and lose weight. The use of oral contraceptives has been shown effective in reducing acne and hirsutism and regulates the menstrual cycle. For women with severe hirsutism, the addition of antiandrogens to estrogen-progestin therapy has significantly improved the results. In cases of anovulatory infertility, the drug of first choice is clomiphene citrate, followed by low-dose gonadotropins. Recently, insulin-sensitizing drugs have been widely prescribed for PCOS patients. They are particularly effective in reducing insulin resistance and improving ovulatory performance. Besides insulin-sensitizing drugs, natural substances, such as inositol, seems to have good efficacy, similar to metformin with fewer side effects. New substances that could be used include statins and natural statins, such as monakolin, alone or combined with myo-inositol. These substances do not have side effects and greatly reduce the hyperandrogenic component in these patients.
The High Energy Modular Ensemble of Satellites (HERMES) project is aimed to realize a modular X/gamma-ray monitor for transient events, to be placed on-board of a nano-satellite bus (e.g. CubeSat). ...This expandable platform will achieve a significant impact on Gamma Ray Burst (GRB) science and on the detection of Gravitational Wave (GW) electromagnetic counterparts: the recent LIGO/VIRGO discoveries demonstrated that the high-energy transient sky is still a field of extreme interest. The very complex temporal variability of GRBs (experimentally verified up to the millisecond scale) combined with the spatial and temporal coincidence between GWs and their electromagnetic counterparts suggest that upcoming instruments require sub-microsecond time resolution combined with a transient localization accuracy lower than a degree. The current phase of the ongoing HERMES project is focused on the realization of a technological pathfinder with a small network (3 units) of nano-satellites to be launched in mid 2020. We will show the potential and prospects for short and medium-term development of the project, demonstrating the disrupting possibilities for scientific investigations provided by the innovative concept of a new “modular astronomy” with nano-satellites (e.g. low developing costs, very short realization time). Finally, we will illustrate the characteristics of the HERMES Technological Pathfinder project, demonstrating how the scientific goals discussed are actually already reachable with the first nano-satellites of this constellation. The detector architecture will be described in detail, showing that the new generation of scintillators (e.g. GAGG:Ce) coupled with very performing Silicon Drift Detectors (SDD) and low noise Front-End-Electronics (FEE) are able to extend down to few keV the sensitivity band of the detector. The technical solutions for FEE, Back-End-Electronics (BEE) and Data Handling will be also described.
PCOS is the most common endocrinopathy among reproductive age women. Approximately 60% of PCOS women have insulin resistance. While the efficacy of metformin in reducing insulin resistance and ...decreasing androgen level has been widely validated, there is no agreement on the dose of metformin to be used.
Prospective non-randomized cohort study of 108 insulin resistant, overweight and obese PCOS women, aged between 22 and 35 years. All patients received 1500 mg of metformin (500 mg x 3 times/day) for the first 6 months. At the end of this period, the patients' HOMA index was evaluated. In subjects, who did not demonstrate normalization of the HOMA index, the dose was increased to 2500 mg/day (500 mg at breakfast and 1000 mg at lunch and dinner) for additional 6 months. The hormonal blood profile, fasting insulin and fasting glucose levels, HOMA index, anthropometric assessment, pelvic ultrasound, FAI index and cholesterol were evaluated.
Overall results showed a good response to metformin therapy in insulin-resistant PCOS patients with BMI >25, while in patients with higher BMI (31.15 ± 0.40), no normalization of HOMA was found. At the higher dose of metformin, obese patients achieved a good response to therapy, with improvement in BMI, menstrual pattern, cholesterol levels and hyperandrogenism.
Our results demonstrate a correlation between the required dose of metformin, BMI and hyperandrogenism. The dose of metformin should be adjusted to patients' BMI in order to obtain significant results in terms of clinical, metabolic and hormonal responses.
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of women of reproductive age and a complex endocrine condition, due to its heterogeneity and uncertainty about its etiology. ...However, PCOS is also associated with other metabolic abnormalities such as insulin resistance, impaired glucose tolerance, and diabetes. There are few medications that are approved for the most common symptoms of PCOS, leading to the off-label use of medications that were approved for other indications. One of the most common medications being used off label for PCOS is metformin. Research of other effective therapeutic options has included the utility of inositol.
A systematic literature search of PubMed was performed using the following combination of terms: 'PCOS', 'hyperandrogenism' 'inositol', 'natural molecules'. Only papers published between 2000 and 2016 were included in our analysis. The present review analyzes all aspects of the choice of natural molecules in the treatment of hyperandrogenism and metabolic disorders in PCOS women.
The rationale underlying the use of inositols as a therapeutic application in PCOS derives from their activities as insulin mimetic agents and their salutary effects on metabolism and hyperandrogenism without side effects.
In this review will discuss the role of a number of natural associations between inositol and different substances in the treatment of hyperandrogenic symptoms in PCOS women.
Abstract Objectives To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational ...complications and neonatal outcome. Study design Our prospective, single centre study included 98 pregnant women with PCOS treated with metformin throughout pregnancy and 110 normal pregnant controls. All PCOS patients were hyperinsulinemic and received metformin (1700–3000 mg/day) before conception and until 37 weeks’ gestation. Results Metformin treatment in the pregnant PCOS patients resulted in significant decrease in miscarriage rate (9.1% vs 20%; p < 0.05), gestational diabetes (0 vs 13%; p < 0.005), and gestational hypertension (0 vs 11%; p < 0.005) and a non-significant decrease in pre-eclampsia (0 vs 3%; p = .24), compared to the control group. Mean neonatal Apgar score, weight and length were comparable between the two groups. Conclusions Continuing metformin therapy throughout pregnancy resulted in significant reduction in pregnancy complications with concomitant improved neonatal outcome, with no serious deleterious side effects.
The Atmospheric Remote-sensing Infrared Exoplanets Large-survey (ARIEL) is the fourth medium (M4) mission selected in the context of the ESA Cosmic Vision 2015–2025 programme, with a launch planned ...in 2028. During 4 years of flight operations, ARIEL will probe the chemical and physical properties of approximately 1000 known exoplanets by observing their atmosphere, to study how planetary systems form and evolve
1
,
2
. The mission is designed as a transit and eclipse spectroscopy survey, operated by a 1-m class telescope feeding two instruments, the Fine Guidance system (FGS) and the ARIEL InfraRed Spectrometer (AIRS), that accommodate photometric and spectroscopic channels covering the band from 0.5 to 7.8 μm in the visible to near-IR range
3
,
4
. The mission high sensitivity requirements ask for an extremely stable thermo-mechanical platform. The payload thermal control is based on a passive and active cooling approach. Passive cooling is achieved by a V-Groove shields system that exploits the L2 orbit favourable thermal conditions to cool the telescope and the optical bench to stable temperatures <60 K. The FGS focal planes operate at the optical bench temperature while the AIRS channel detectors require a colder reference, lower than 42 K. This is provided by an active cooling system based on a Neon Joule-Thomson cold end, fed by a mechanical compressor. In this paper we report the thermal architecture of the payload at the end of Phase B1 and present the requirements that drive the design together with the analyses results and the expected performances.
PDF
